

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/250095 A1

(51) International Patent Classification:

A61L 27/36 (2006.01) A61F 2/14 (2006.01)

A61L 27/54 (2006.01) A61K 9/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/065460

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

09 June 2021 (09.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20179055.7 09 June 2020 (09.06.2020) EP

(71) Applicant: **DOMPE' FARMACEUTICI SPA** [IT/IT];
Via Santa Lucia 6, 20121 Milano (IT).

(72) Inventors: **ACERRA, Giuseppina**; c/o Dompe' Farmaceutici SpA, Via Pietro Castellino, 111, 80131 Napoli (IT). **DETTA, Nicola**; c/o Dompe' Farmaceutici SpA, Via Pietro Castellino, 111, 80131 Napoli (IT). **PANDOLFI, Assunta**; c/o Università degli Studi G. d' Annunzio Chieti, Pescara, Via di Vestini 31, 66100 Chieti (IT). **MASTROPASQUA, Leonardo**; c/o Università degli Studi G. d' Annunzio Chieti, Pescara, Via di Vestini 31, 66100 Chieti (IT). **NUBILE, Mario**; c/o Università degli Studi G. d' Annunzio Chieti, Pescara, Via di Vestini 31, 66100 Chieti (IT). **MANDA-TORI, Domitilla**; Università degli Studi G. d' Annunzio Chieti, Pescara, Via di Vestini 31, 66100 Chieti (IT).

(74) Agent: **MAURI, Elisabetta Maria Ester**; c/o Dompe' Farmaceutici SpA, Via Santa Lucia 6, 20121 Milano (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: NEW DRUG DELIVERY SYSTEM FOR OPHTHALMIC USE

(57) Abstract: Object of the present invention is a drug delivery system comprising a decellularized corneal stroma scaffold having dispersed within and/or bound to its surface microparticles containing at least one pharmaceutically active molecule dispersed in a matrix having a composition consisting for at least 70% of polylactic co-glycolic acid (PLGA).

WO 2021/250095 A1